Notice of Investigation – Pericarditis – Focused

Overview

The Veterans' Entitlements Act 1986, enacted by the Commonwealth Parliament, was introduced to address the need for comprehensive provisions governing the entitlements of veterans, including their families, in recognition of their service and sacrifices. One of the key objectives of this Act is to ensure that veterans receive appropriate pensions and compensation for service-related injuries and disabilities. The Repatriation Medical Authority, established under this Act, plays a critical role in determining the eligibility of veterans for various benefits and in reviewing medical evidence to support claims. In response to emerging health concerns, the Authority is mandated to investigate new scientific literature that may impact existing statements of principles related to specific health conditions, such as pericarditis in the context of the Novavax COVID-19 vaccine. This proactive approach aims to ensure that the entitlements provided under the Act remain relevant and based on the latest medical research. The Authority's call for submissions from relevant stakeholders, including veterans, medical experts, and advocacy groups, underscores its commitment to a thorough and inclusive review process.

Scope and Application

The Repatriation Medical Authority (the Authority) under the Veterans' Entitlements Act 1986 has announced its intention to investigate new scientific literature concerning the Novavax COVID-19 vaccine in relation to pericarditis, as stipulated in section 196G of the Act. This investigation will specifically address the Statements of Principles Instrument Nos. 90 & 91 of 2023, focusing on pericarditis. Eligible individuals for this investigation include those who can claim pensions under Part II or Part IV of the VEA, those eligible for compensation under section 319 of the Military Rehabilitation and Compensation Act 2004, organisations representing various veteran groups, the Repatriation Commission or the Military Rehabilitation and Compensation Commission, and experts in relevant fields. The Authority invites written submissions from these groups, which must be submitted electronically via the RMA website, by email, or by post by 27 January 2026. The first meeting for this investigation will be held on 3 February 2026, and the RMA Secretariat can be contacted for further assistance or to obtain the RMA Submission Guidelines. This investigation is conducted within the Commonwealth jurisdiction and applies to those within its scope, with no stated exclusions or exemptions in the notice provided.

Key Provisions

Section 196G of the Veterans' Entitlements Act 1986 (the VEA) requires the Repatriation Medical Authority (the Authority) to conduct an investigation into new scientific literature concerning the "Novavax (Nuvaxovid, NVX-CoV2373) COVID-19 vaccine" in the context of pericarditis. This investigation is to be conducted under Statements of Principles Instrument Nos. 90 & 91 of 2023 concerning pericarditis. The Authority invites submissions from specific groups, including those eligible to make claims under the VEA and MRCA, organisations representing veterans or their dependants, the Repatriation Commission or Military Rehabilitation and Compensation Commission, and persons with expertise relevant to the investigation. Submissions can be made electronically via the RMA website, by email, or by post, and must be received by 27 January 2026. The Act imposes obligations on the Authority to initiate and conduct the investigation in accordance with the stated provisions and timelines. It also mandates that submissions from eligible parties be considered and evaluated as part of the investigation process. Furthermore, the Authority must ensure that all submissions are received by the specified deadline and that the investigation is held in a manner that allows for comprehensive and thorough analysis of the scientific literature. Under the Act, there are no specific offences or penalties mentioned for failing to comply with the submission requirements. However, the importance of adhering to the deadlines and submission guidelines is underscored by the necessity of comprehensive and timely input for the investigation. The Authority may consider the relevance and quality of submissions when conducting the investigation, but no direct penalties are specified for non-compliance with the submission process. The primary focus is on ensuring that all relevant perspectives and expertise are incorporated into the investigation to provide a well-rounded analysis of the scientific literature concerning the Novavax COVID-19 vaccine and pericarditis.